Home
 /
Papers
 /
Molecular Biology
 /
Mechanistic insight into the phosphorylation of ERK by MEK
Preprint
Open access
V1
Top 1% · Validated by QED

Mechanistic insight into the phosphorylation of ERK by MEK

Ying Sun, Chen Peng, Shengjie Liu +4 more
March 2026
 ·
bioRxiv
 ·
DOI 
10.64898/2026.03.13.710243
94
%
Reproducible
QED Impressions
This paper passed independent validation.
QED's automated review checked the evidence supporting each claim, the statistical methods, and whether the results are reproducible from the data provided.

It ranks in the top 1% of preprints assessed in Molecular Biology this quarter.
Run full QED analysis
Read paper
Save

Why this is interesting

Overturning the canonical ERK activation model, this study delivers the first active pMEK1–ERK1 structures and reveals a phosphate-relay mechanism and MEK1 phosphatase activity, reshaping therapeutic targeting of a pathway driving 30% of human cancers.

QED claims analysis

Summary

Cryo-EM structures of phosphorylated MEK1 bound to ERK1 reveal that MEK1 interacts with ERK1 through three specific interfaces and functions as a multifunctional enzyme that not only catalyzes canonical ATP-dependent phosphorylation of ERK1 at Y204 and T202, but also exhibits phosphatase activity to dephosphorylate Y204 and catalyzes an unprecedented relay mechanism in which the phosphate group is transferred from Y204 to T202, establishing a dual-pathway catalytic cycle driven by nucleotide-dependent changes in binding affinity.

See full analysis
Main Claim 1 –

pMEK1 Binds ERK1 via DRS, FRS, and Activation Loops

Supporting evidence

  • MEK1 Phosphorylation Enables Stable ERK1 Binding and Phosphorylation
  • ERK1 H142 and K276 Are Critical for MEK1 Phosphorylation
Main Claim 2 –

ERK1 Activation Loop Inserts Y204 into MEK1 Catalytic Pocket

Supporting evidence

  • MEK1 D190, K192, and D208 Are Essential Catalytic Residues
Main Claim 3 –

MEK1 Activation Requires Activation Loop, αC-Helix, and αA-Helix Shifts

Main Claim 4 –

pMEK1 Dephosphorylates ERK1 Y204 via Phosphatase Activity

Abstract

The RAS-RAF-MEK-ERK cascade regulates critical cellular processes such as cell proliferation and differentiation, with its dysregulation driving over 30% of human cancers. However, the active state of MEK and molecular mechanisms of ERK phosphorylation remain unclear. Here, we report the cryo-EM structures of phosphorylated MEK1 (pMEK1) bound to unphosphorylated and monophosphorylated ERK1. These structures reveal that pMEK1 interacts with ERK1 via three interfaces: first between MEK1 N-terminal peptide and ERK1 D-site recruitment site (DRS), second between MEK1 C-lobe and ERK1 F-site recruitment site (FRS), and third between MEK1 activation loop and ERK1 activation loop. Notably, we identify an unexpected phosphorylation mechanism: pMEK1 catalyzes ERK1 T202 phosphorylation through phosphate transfer from ERK1 Y204. In addition, pMEK1 exhibits phosphatase activity, catalyzing the dephosphorylation of ERK1 Y204. These findings allow us to delineate the catalytic cycle of MEK-catalyzed ERK phosphorylation and provide insights for targeting this oncogenic pathway.

Related papers

How the QED Score works

QED Score is a validated AI-based quality metric that evaluates life science papers on two dimensions: originality and validity. Each manuscript is anonymized, broken down into its claims and supporting evidence, and examined by specialized AI agents for statistical rigor, consistency across figures, and fit with the existing literature. Scores are percentile ranks, so they're comparable across fields. In blinded tests, expert professors sided with QED Score over journal rank in 75% of decisive cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?